Revumenib wurde letztes Jahr als erster Arzneistoff seiner Art zur Behandlung von akuten Leukämien zugelassen.
Genau genommen geht es um eine Art von Leukämie, die bisher schlechte Behandlungsaussichten hatte. 🧵
Genau genommen geht es um eine Art von Leukämie, die bisher schlechte Behandlungsaussichten hatte. 🧵
January 19, 2025 at 10:29 AM
Revumenib wurde letztes Jahr als erster Arzneistoff seiner Art zur Behandlung von akuten Leukämien zugelassen.
Genau genommen geht es um eine Art von Leukämie, die bisher schlechte Behandlungsaussichten hatte. 🧵
Genau genommen geht es um eine Art von Leukämie, die bisher schlechte Behandlungsaussichten hatte. 🧵
2024 approvals: Summary of 12 new 💊indications in heme malignancies by FDA:
1. #Zanubrutinib
2. #Ponatinib
3. #LisoCel x2
4. #Imetelstat
5. #Epcortimab
6. #Daratumuab
7. #Axatilimab
8. #Isatuximab
9. #Asciminib
10. #ObiCel
11. #Revumenib
#HemeSky #OncSky #mmsm #leusm #MedSky #lymsm
1. #Zanubrutinib
2. #Ponatinib
3. #LisoCel x2
4. #Imetelstat
5. #Epcortimab
6. #Daratumuab
7. #Axatilimab
8. #Isatuximab
9. #Asciminib
10. #ObiCel
11. #Revumenib
#HemeSky #OncSky #mmsm #leusm #MedSky #lymsm
December 24, 2024 at 3:07 AM
2024 approvals: Summary of 12 new 💊indications in heme malignancies by FDA:
1. #Zanubrutinib
2. #Ponatinib
3. #LisoCel x2
4. #Imetelstat
5. #Epcortimab
6. #Daratumuab
7. #Axatilimab
8. #Isatuximab
9. #Asciminib
10. #ObiCel
11. #Revumenib
#HemeSky #OncSky #mmsm #leusm #MedSky #lymsm
1. #Zanubrutinib
2. #Ponatinib
3. #LisoCel x2
4. #Imetelstat
5. #Epcortimab
6. #Daratumuab
7. #Axatilimab
8. #Isatuximab
9. #Asciminib
10. #ObiCel
11. #Revumenib
#HemeSky #OncSky #mmsm #leusm #MedSky #lymsm
Listen to my MSK colleague Eytan Stein "Revumenib Could Provide New Path to Transplant in R/R KMT2A+ Acute Leukemia" @mskcancercenter.bsky.social #leusm #ASH24 @onclive.bsky.social www.onclive.com/view/revumen...
Revumenib Could Provide New Path to Transplant in R/R KMT2A Acute Leukemia
Eytan M. Stein, MD, discusses the significance of the FDA approval of revumenib for relapsed/refractory acute leukemia with KMT2A rearrangements.
www.onclive.com
December 6, 2024 at 7:29 PM
Listen to my MSK colleague Eytan Stein "Revumenib Could Provide New Path to Transplant in R/R KMT2A+ Acute Leukemia" @mskcancercenter.bsky.social #leusm #ASH24 @onclive.bsky.social www.onclive.com/view/revumen...
Congrats to Eytan Stein & collaborators on receiving "2025 Paper of the Year” from @jco-asco.bsky.social for their study evaluating revumenib for acute #leukemia with a KMT2A translocation. Study results led to the drug's FDA approval in 2024. @mskcancercenter.bsky.social
➡️ https://bit.ly/3LH5G2R
➡️ https://bit.ly/3LH5G2R
FDA Approves Revumenib, a Menin Inhibitor, for Aggressive Leukemia
Based on a clinical trial led by an MSK investigator, the FDA has approved revumenib (Revuforj®) for patients 1-year-old and older who have leukemia that has come back after treatment and whose cancer...
www.mskcc.org
January 14, 2026 at 7:28 PM
Congrats to Eytan Stein & collaborators on receiving "2025 Paper of the Year” from @jco-asco.bsky.social for their study evaluating revumenib for acute #leukemia with a KMT2A translocation. Study results led to the drug's FDA approval in 2024. @mskcancercenter.bsky.social
➡️ https://bit.ly/3LH5G2R
➡️ https://bit.ly/3LH5G2R
It’s always a great start to the day to learn we have one more drug to offer patients with r/r leukemia! 🎗️🩸💊 www.fda.gov/drugs/resour...
FDA approves revumenib for relapsed or refractory acute leukemia
On November 15, 2024, the FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.) for relapsed or refractory acute leukemia with a KMT2A translocation.
www.fda.gov
November 17, 2024 at 2:23 PM
It’s always a great start to the day to learn we have one more drug to offer patients with r/r leukemia! 🎗️🩸💊 www.fda.gov/drugs/resour...
Late Friday drug approval: FDA authorizes Syndax's menin inhibitor revumenib to treat a targeted acute leukemia population with KMT2A translocations. Brand name Revuforji: www.fda.gov/drugs/resour...
FDA approves revumenib for relapsed or refractory acute leukemia
On November 15, 2024, the FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.) for relapsed or refractory acute leukemia with a KMT2A translocation.
www.fda.gov
November 15, 2024 at 9:24 PM
Late Friday drug approval: FDA authorizes Syndax's menin inhibitor revumenib to treat a targeted acute leukemia population with KMT2A translocations. Brand name Revuforji: www.fda.gov/drugs/resour...
Excited to share our preprint (manuscript in review): TP53 Inactivation Confers Resistance to the Menin Inhibitor Revumenib in Acute Myeloid Leukemia.
@ucsfcancer.bsky.social
www.biorxiv.org/content/10.1...
@ucsfcancer.bsky.social
www.biorxiv.org/content/10.1...
TP53 Inactivation Confers Resistance to the Menin Inhibitor Revumenib in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a heterogeneous cancer that is associated with poor outcomes. Revumenib and other menin inhibitors have shown promising activity against AMLs with KMT2A -rearrangements...
www.biorxiv.org
March 31, 2025 at 3:57 AM
Excited to share our preprint (manuscript in review): TP53 Inactivation Confers Resistance to the Menin Inhibitor Revumenib in Acute Myeloid Leukemia.
@ucsfcancer.bsky.social
www.biorxiv.org/content/10.1...
@ucsfcancer.bsky.social
www.biorxiv.org/content/10.1...
Etwa 10% aller akuten Leukämien weisen Veränderungen in einem KMT2A genannten Gen auf. Diese Leukämien haben bisher außerdem schlechte Prognosen.
Zur Behandlung dieser Form der Leukämie wurde Revumenib entwickelt. ⬇️
Zur Behandlung dieser Form der Leukämie wurde Revumenib entwickelt. ⬇️
January 19, 2025 at 10:29 AM
Etwa 10% aller akuten Leukämien weisen Veränderungen in einem KMT2A genannten Gen auf. Diese Leukämien haben bisher außerdem schlechte Prognosen.
Zur Behandlung dieser Form der Leukämie wurde Revumenib entwickelt. ⬇️
Zur Behandlung dieser Form der Leukämie wurde Revumenib entwickelt. ⬇️
a huge thanks to a patient of mine who was willing to share his story with @theaacr.bsky.social regarding being treated with Aza + Ven + Revumenib as part of the BEAT AML study and to advocate for cancer research funding!
cancerprogressreport.aacr.org/report/survi...
cancerprogressreport.aacr.org/report/survi...
Back on the Golf Course Rebuilding His Game, Thanks to a Clinical Study
Jack Moorman was diagnosed with acute myeloid leukemia at age 65. He participated in a clinical trial of a new targeted therapy called revumenib, which has kept his cancer in check.
cancerprogressreport.aacr.org
September 17, 2025 at 4:15 PM
a huge thanks to a patient of mine who was willing to share his story with @theaacr.bsky.social regarding being treated with Aza + Ven + Revumenib as part of the BEAT AML study and to advocate for cancer research funding!
cancerprogressreport.aacr.org/report/survi...
cancerprogressreport.aacr.org/report/survi...
October 25, 2025 at 1:06 AM
Dadurch wird aus der betroffenen Zelle eine Tumorzelle.
Um die Expression dieser Gene zu erhöhen braucht KMT2A allerdings einen Partner, das Protein Menin.
Revumenib verhindert die Interaktion zwischen KMT2A und Menin, was wiederum das veränderte KMT2A an der falschen Genregulation hindert.
Um die Expression dieser Gene zu erhöhen braucht KMT2A allerdings einen Partner, das Protein Menin.
Revumenib verhindert die Interaktion zwischen KMT2A und Menin, was wiederum das veränderte KMT2A an der falschen Genregulation hindert.
January 19, 2025 at 10:29 AM
Dadurch wird aus der betroffenen Zelle eine Tumorzelle.
Um die Expression dieser Gene zu erhöhen braucht KMT2A allerdings einen Partner, das Protein Menin.
Revumenib verhindert die Interaktion zwischen KMT2A und Menin, was wiederum das veränderte KMT2A an der falschen Genregulation hindert.
Um die Expression dieser Gene zu erhöhen braucht KMT2A allerdings einen Partner, das Protein Menin.
Revumenib verhindert die Interaktion zwischen KMT2A und Menin, was wiederum das veränderte KMT2A an der falschen Genregulation hindert.
Revumenib Displays Activity in Relapsed/Refractory KMT2Ar Acute Leukemias @ash-hematology.bsky.social #ASH24 #leusm #oncology www.onclive.com/view/revumen...
Revumenib Displays Activity in Relapsed/Refractory KMT2Ar Acute Leukemias
Revumenib demonstrated meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia.
www.onclive.com
December 8, 2024 at 1:57 AM
Revumenib Displays Activity in Relapsed/Refractory KMT2Ar Acute Leukemias @ash-hematology.bsky.social #ASH24 #leusm #oncology www.onclive.com/view/revumen...
Important approval in a difficult to treat cohort leukemia #revumenib, a menin inhibitor, for #relapsedAML with #KMT2Atranslocation in adult and pediatric patients 1 year and older.
www.fda.gov/drugs/resour...
www.fda.gov/drugs/resour...
FDA approves revumenib for relapsed or refractory acute leukemia
On November 15, 2024, the FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.) for relapsed or refractory acute leukemia with a KMT2A translocation.
www.fda.gov
November 15, 2024 at 10:22 PM
Important approval in a difficult to treat cohort leukemia #revumenib, a menin inhibitor, for #relapsedAML with #KMT2Atranslocation in adult and pediatric patients 1 year and older.
www.fda.gov/drugs/resour...
www.fda.gov/drugs/resour...
Congratulations to Syndax on the approval of first Menin inhibitor! It thrills me to see a new drug for adult AND pediatric leukemia patients. On a dark day for our industry, this is a reminder of the incredible talent and science that we bring to the world.
www.cancernetwork.com/view/fda-app...
www.cancernetwork.com/view/fda-app...
FDA Approves Revumenib for Relapsed/Refractory KMT2A-Translocated Acute Leukemia
The FDA has approved revumenib (Revuforj) for the treatment of patients with relapsed/refractory acute leukemia with a KMT2A translocation in adult and pediatric patients 1 year and older.
www.cancernetwork.com
November 15, 2024 at 9:55 PM
Congratulations to Syndax on the approval of first Menin inhibitor! It thrills me to see a new drug for adult AND pediatric leukemia patients. On a dark day for our industry, this is a reminder of the incredible talent and science that we bring to the world.
www.cancernetwork.com/view/fda-app...
www.cancernetwork.com/view/fda-app...
23 Prozent Remission bei einem Blutkrebs, für den es kaum Optionen gab. Der erste Menin-Inhibitor für die häufigste AML-Mutation ist jetzt zugelassen.
Revumenib: Erster Menin-Inhibitor für NPM1-Leukämie
Für Patienten mit der häufigsten AML-Mutation gibt es erstmals eine zielgerichtete Therapie: Die FDA hat Revumenib für NPM1-mutierte Leukämie zugelassen. Die Kombinationsdaten zeigen Ansprechraten von 100 Prozent.
denkstrom.org
July 11, 2026 at 1:31 PM
23 Prozent Remission bei einem Blutkrebs, für den es kaum Optionen gab. Der erste Menin-Inhibitor für die häufigste AML-Mutation ist jetzt zugelassen.
On n'avait pas de masque en plein pic pandémique, une pénurie de paracétamol et d'autres médicaments en 2022. On est en pleine pénurie de revuménib qui sert à lutter contre les leucémies agressives.
Alors vous pensez bien qu'on n'allait pas avoir une gestion merveilleuse des lunettes pour l'éclipse
Alors vous pensez bien qu'on n'allait pas avoir une gestion merveilleuse des lunettes pour l'éclipse
August 11, 2026 at 6:45 PM
On n'avait pas de masque en plein pic pandémique, une pénurie de paracétamol et d'autres médicaments en 2022. On est en pleine pénurie de revuménib qui sert à lutter contre les leucémies agressives.
Alors vous pensez bien qu'on n'allait pas avoir une gestion merveilleuse des lunettes pour l'éclipse
Alors vous pensez bien qu'on n'allait pas avoir une gestion merveilleuse des lunettes pour l'éclipse
Exciting to see the first results from the INTERCEPT platform study (PI Andrew Wei) expertly presented by Dr. Sun Loo from @petermaccc.bsky.social at #ASH24. Intervening with a molecularly rational approach at early #MRD relapse is feasible in AML and the results with revumenib are encouraging.
December 7, 2024 at 11:25 PM
Exciting to see the first results from the INTERCEPT platform study (PI Andrew Wei) expertly presented by Dr. Sun Loo from @petermaccc.bsky.social at #ASH24. Intervening with a molecularly rational approach at early #MRD relapse is feasible in AML and the results with revumenib are encouraging.
This is amazing. Menin inhibitors FDA approved! Such a quick turnaround from drug discovery, to molecular mechanisms and on to clinical trials showing efficacy and favourable safety profile.
A huge win for the field of epigenetic targeted drugs! Kudos to all involved.
www.fda.gov/drugs/resour...
A huge win for the field of epigenetic targeted drugs! Kudos to all involved.
www.fda.gov/drugs/resour...
FDA approves revumenib for relapsed or refractory acute leukemia
On November 15, 2024, the FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.) for relapsed or refractory acute leukemia with a KMT2A translocation.
www.fda.gov
November 24, 2024 at 7:33 PM
This is amazing. Menin inhibitors FDA approved! Such a quick turnaround from drug discovery, to molecular mechanisms and on to clinical trials showing efficacy and favourable safety profile.
A huge win for the field of epigenetic targeted drugs! Kudos to all involved.
www.fda.gov/drugs/resour...
A huge win for the field of epigenetic targeted drugs! Kudos to all involved.
www.fda.gov/drugs/resour...
23 Prozent Remission bei einem Blutkrebs, für den es kaum Optionen gab. Der erste Menin-Inhibitor für die häufigste AML-Mutation ist jetzt zugelassen.
Revumenib: Erster Menin-Inhibitor für NPM1-Leukämie
Für Patienten mit der häufigsten AML-Mutation gibt es erstmals eine zielgerichtete Therapie: Die FDA hat Revumenib für NPM1-mutierte Leukämie zugelassen. Die Kombinationsdaten zeigen Ansprechraten von 100 Prozent.
denkstrom.org
June 17, 2026 at 1:31 PM
23 Prozent Remission bei einem Blutkrebs, für den es kaum Optionen gab. Der erste Menin-Inhibitor für die häufigste AML-Mutation ist jetzt zugelassen.
FDA Novel Drug approvals in 2024 - Chris De Savi
@fda.gov
oncodaily.com/blog/215120
#Acoramidis #AcuteLeukemia #ArrhythmiaManagement #BiliaryTractCancer #Cancer #CancerCell #CellGrowth #DrugDiscovery #FDA #GeneticDisorders #Landiolol #Medicine #OncoDaily #Oncology #Revumenib #SVTtherapies
@fda.gov
oncodaily.com/blog/215120
#Acoramidis #AcuteLeukemia #ArrhythmiaManagement #BiliaryTractCancer #Cancer #CancerCell #CellGrowth #DrugDiscovery #FDA #GeneticDisorders #Landiolol #Medicine #OncoDaily #Oncology #Revumenib #SVTtherapies
Chris De Savi: FDA Novel Drug approvals in 2024 - OncoDaily
Chris De Savi: FDA Novel Drug approvals in 2024 / Acoramidis, acute leukemia, arrhythmia management, Biliary tract cancer, cancer, Cancer Cell, cell growth,
oncodaily.com
January 2, 2025 at 5:31 PM
FDA Novel Drug approvals in 2024 - Chris De Savi
@fda.gov
oncodaily.com/blog/215120
#Acoramidis #AcuteLeukemia #ArrhythmiaManagement #BiliaryTractCancer #Cancer #CancerCell #CellGrowth #DrugDiscovery #FDA #GeneticDisorders #Landiolol #Medicine #OncoDaily #Oncology #Revumenib #SVTtherapies
@fda.gov
oncodaily.com/blog/215120
#Acoramidis #AcuteLeukemia #ArrhythmiaManagement #BiliaryTractCancer #Cancer #CancerCell #CellGrowth #DrugDiscovery #FDA #GeneticDisorders #Landiolol #Medicine #OncoDaily #Oncology #Revumenib #SVTtherapies
check out our work now in the latest issue of BJH!
We report on the efficacy of therapies in patients with acute leukemia previously treated with revumenib
onlinelibrary.wiley.com/doi/10.1111/...
We report on the efficacy of therapies in patients with acute leukemia previously treated with revumenib
onlinelibrary.wiley.com/doi/10.1111/...
January 21, 2026 at 5:00 PM
check out our work now in the latest issue of BJH!
We report on the efficacy of therapies in patients with acute leukemia previously treated with revumenib
onlinelibrary.wiley.com/doi/10.1111/...
We report on the efficacy of therapies in patients with acute leukemia previously treated with revumenib
onlinelibrary.wiley.com/doi/10.1111/...
We’re excited to celebrate the FDA approval of revumenib, a menin inhibitor, for relapsed or refractory acute leukemia with a KMT2A translocation. We’re proud of the dedication and innovation that have led to a new therapy now available to patients who need it most.
Learn more: bit.ly/3UYY90B
Blocking the Connection | Dana-Farber Cancer Institute
The story of research in menin and its relation to cancer — from early efforts to understand how the cell makes use of menin, to explorations of the cell machinery operated by menin, to the developmen...
bit.ly
November 25, 2024 at 5:48 PM
We’re excited to celebrate the FDA approval of revumenib, a menin inhibitor, for relapsed or refractory acute leukemia with a KMT2A translocation. We’re proud of the dedication and innovation that have led to a new therapy now available to patients who need it most.
Learn more: bit.ly/3UYY90B
#ASH25 (Abs 47): Encouraging early results (N=21, median age 70 y) from ph2 SAVE trial of all-oral regimen: revumenib + decitabine/cedazuridine + venetoclax in ND NPM1- or KMT2A-mutated AML. 86% ORR, 81% CR/CRh. #Medsky #cansky #oncsky #AML
www.cancercommunicator.com/oral-menin-b...
www.cancercommunicator.com/oral-menin-b...
December 6, 2025 at 6:03 PM
First-in-class menin inhibitor remuvenib got approved by the US FDA for a R/R acute leukemia with a KMT2A translocation www.fda.gov/drugs/resour...
FDA approves revumenib for relapsed or refractory acute leukemia
On November 15, 2024, the FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.) for relapsed or refractory acute leukemia with a KMT2A translocation.
www.fda.gov
November 18, 2024 at 11:02 PM
First-in-class menin inhibitor remuvenib got approved by the US FDA for a R/R acute leukemia with a KMT2A translocation www.fda.gov/drugs/resour...